NFE2L2 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Notably, GCLC and HMOX1 have been described as NFE2L2 (NRF2) targets (Yan et al, 2023; Yang et al, 2023b), a pathway reported to be active in tRCC (Bakouny et al, 2022).